OSI-7904L
Term · Oncology and biomedicine · MLC-T-ONC-006165
A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called thymidylate synthase inhibitors.
A liposome-encapsulated formulation of the benzoquinazoline folate analog OSI-7904 with antineoplastic activity. As a thymidylate synthase inhibitor, OSI-7904 noncompetitively binds to thymidylate synthase, resulting in inhibition of thymine nucleotide synthesis and DNA replication. Liposome encapsulation improves the efficacy and increases the half-life of OSI-7904.
| Identifier | MLC-T-ONC-006165 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | OSI-7904 liposomal |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-006165",
"term": "OSI-7904L",
"field": "Oncology and biomedicine",
"definitions": [
"A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called thymidylate synthase inhibitors.",
"A liposome-encapsulated formulation of the benzoquinazoline folate analog OSI-7904 with antineoplastic activity. As a thymidylate synthase inhibitor, OSI-7904 noncompetitively binds to thymidylate synthase, resulting in inhibition of thymine nucleotide synthesis and DNA replication. Liposome encapsulation improves the efficacy and increases the half-life of OSI-7904."
],
"expansions": [
"OSI-7904 liposomal"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/osi-7904l/"
}
Record 12,368 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.